Business Context and Reporting Period
This Form 8-K was filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on January 25, 2019. The report details the termination of a material definitive agreement regarding a loan facility with Silicon Valley Bank (SVB).
Key Financial Metrics
- Outstanding Borrowings Repaid: Approximately $8.9 million.
- Outstanding Interest and Fees Repaid: Approximately $1 million.
- Final Payment Fee: 10% of the original aggregate principal amount funded and drawn ($10 million), totaling $1 million.
- Total Repayment: Approximately $10.9 million (principal, interest, and fees).
- Remaining Obligations: A success fee of 3.5% of the funded principal ($10 million) remains contingent on specific future events (FDA approval, sale of assets, or change of control) occurring by July 24, 2024.
- Warrants: A warrant to purchase 36,000 shares of common stock remains outstanding and exercisable.
Material Changes
On January 25, 2019, the Company agreed to prepay in full all outstanding indebtedness under its Loan and Security Agreement with SVB, effective January 28, 2019. This action terminated all unfunded commitments and released security interests and liens held by SVB, except for those specified as surviving termination. The prepayment was triggered by the Company's decision to satisfy the loan terms, which required prepayment if a Pre-Clinical Event did not occur by September 30, 2019, or if unrestricted cash balances fell below $18 million.
Outlook, Risks, and Contingencies
- Surviving Obligations: Despite the payoff, the Company retains indemnity obligations and a contingent success fee of 3.5% of the funded principal ($350,000) payable if FDA approval for gemcabene is received, or if a change of control or asset sale occurs by July 24, 2024.
- Continuing Relationships: The Company will continue to maintain bank services with SVB, including business credit cards, and must provide cash collateral to support these obligations.
- Warrant Liability: The warrant issued to SVB for 36,000 shares remains active.
Investor Verification Checklist
- Verify the exact cash outflow of approximately $10.9 million and its impact on the Company's current liquidity position.
- Confirm the status of the "Pre-Clinical Event" milestone and the timeline for potential FDA approval of gemcabene to assess the risk of the 3.5% success fee.
- Review the terms of the remaining warrant for 36,000 shares to understand potential dilution.
- Check subsequent filings for any changes in the Company's cash collateral requirements for SVB credit card obligations.